A Randomized, Double-blind, Placebo-controlled, Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 Administered Orally to Healthy Male and Female Participants
Latest Information Update: 12 Feb 2021
At a glance
- Drugs Vornorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Taisho Pharmaceutical
- 05 Feb 2021 Status changed from recruiting to completed.
- 30 Sep 2020 Status changed from not yet recruiting to recruiting.
- 15 Jul 2020 New trial record